RT Journal Article
SR Electronic
T1 SPTLC1 p.Leu38Arg, a novel mutation associated with childhood ALS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.07.22269609
DO 10.1101/2022.02.07.22269609
A1 Museer A. Lone
A1 Sen Zeng
A1 Florence Bourquin
A1 Mengli Wang
A1 Shunxiang Huang
A1 Zhiqiang Lin
A1 Beisha Tang
A1 Ruxu Zhang
A1 Thorsten Hornemann
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.07.22269609.abstract
AB Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease. Recently, several gain-of-function mutations in SPTLC1 were associated with juvenile ALS. SPTLC1 encodes for a subunit of the serine-palmitoyltransferase (SPT) - the rate-limiting enzyme in the de novo synthesis of sphingolipids (SL).Here we identified a novel SPTLC1p.L38R mutation in a young Chinese girl with a signature of juvenile ALS. The patient presented with muscular weakness and atrophy, tongue tremor and fasciculation, breathing problems and positive pyramidal signs. A blood lipid analysis showed overall increased SL levels and particularly a pronounced increase in dihydro-SL species. Increased SL de novo synthesis was confirmed in an SPTLC1 deficient HEK cell model that expressed the mutant form. An experimental therapy based on extracts of the fungus C. cicadae resulted in a significant lowering of plasma sphingolipids. A subsequent metabolomics analysis identified Myriocin, a potent SPT inhibitor as an active component of the extract. The inhibitory effect of the C. cicadae extract on SL de novo synthesis was confirmed in a HepG2 cell model. These results suggest that a pharmacological inhibition of SPT could be a therapeutic option for this form of ALS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFoundation Suisse de recherche sur le maladies musculaires, FSRMM (M.A.L). National Natural Science Fund of China grant 81771366 and 82171172 (R.Z). The Swiss National Science Foundation SNF 31003A_179371 (T.H) and European Joint Programme on Rare Diseases, EJP RD+SNF 32ER30_187505 (T.H.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for human subject research studies described in this paper was obtained from Institutional Review Board of the Third Xiangya Hospital in Central South University, China (protocol no. 21096). decision: study approvedI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.